Discover and read the best of Twitter Threads about #bedrest
Most recents (2)
Today marks the end of an era: publication of the final philatelic vignette (authors.elsevier.com/a/1g-uM5qq8Xpp3) co-authored by Robert Kyle @MayoClinic. Bob turned 95 this year and decided to step down from helping prepare these. He published his first vignette @JAMA_current back in 1969!/1 
This longstanding series focused on medical & scientific-themed postage stamps began in 1961. At the 109th Annual Meeting of @AmerMedicalAssn in the then-new convention center in Miami Beach, Florida in June 1960, John Mirt (1897-1968) discussed “Medical Pathfinders on Stamps”./2
At the time, Mr. Mirt – a devoted Freemason - worked in press relations for the AMA in Chicago. After the meeting, he was asked by then-editor of @JAMA_current John Talbott (1902-1990) to start composing short articles about physicians & scientists featured on postage stamps./3
Day 3 of #Omicron symptoms was my worst so far, with fatigue & a very heavy head, alongside sneezing. My tight chest, feeling of reduced lung capacity and tickly lung sensation had subsided slightly, as did the coughing, that had become painful on Day 2 #Oximeter down to 96%...
...so I slept a lot on Day 3.
But now it's 1am on Day 4 and I feel full of life. Fatigue gone. No more headache. Slight wheeze still, Oximeter 96%; no appetite, but sense of smell and taste are fine.
Wonder whether the worst is over, as I'm double AZ-jabbed plus Pfizer-boosted?
But now it's 1am on Day 4 and I feel full of life. Fatigue gone. No more headache. Slight wheeze still, Oximeter 96%; no appetite, but sense of smell and taste are fine.
Wonder whether the worst is over, as I'm double AZ-jabbed plus Pfizer-boosted?
I can't find evidence of people relapsing into worsening symptoms post-Day 3, but my lungs are my weakness... Am I good right now because I slept so much over the last 3 days?
Tomorrow I begin my participation in the @UniofOxford #Molnupiravir (antiviral) trial.
Link follows...
Tomorrow I begin my participation in the @UniofOxford #Molnupiravir (antiviral) trial.
Link follows...
